3,250 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Paloma Partners Management Co

Paloma Partners Management Co acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,250 shares of the biopharmaceutical company’s stock, valued at approximately $486,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth $30,000. Quent Capital LLC grew its position in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $52,000. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 7,093 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total value of $1,851,273.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,168,101. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,168,101. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The disclosure for this sale can be found here. Insiders have sold 74,450 shares of company stock worth $15,287,984 over the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $1.44 during trading hours on Monday, reaching $236.28. The company had a trading volume of 455,953 shares, compared to its average volume of 879,335. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $263.73. The business has a fifty day simple moving average of $200.71 and a 200-day simple moving average of $172.70. The company has a market cap of $29.89 billion, a price-to-earnings ratio of -88.16 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same quarter in the prior year, the business earned ($1.40) EPS. The firm’s revenue for the quarter was up 54.8% compared to the same quarter last year. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ALNY shares. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. UBS Group upped their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research report on Friday, June 28th. Royal Bank of Canada upped their price target on Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company an “outperform” rating in a research report on Tuesday, June 25th. Finally, Evercore ISI upped their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $256.73.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.